GC
JNCE

Grace Capital’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Grace Capital’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$216K Hold
25,928
– – 0.13% 135
2021
Q3 		$234K Buy
25,928
+7,259
+39% +$45K 0.14% 134
2021
Q2 		$127K Buy
18,669
+5,941
+47% +$49.4K 0.09% 153
2021
Q1 		$131K Buy
12,728
+7,720
+154% +$84.6K 0.08% 172
2020
Q4 		$35K Buy
+5,008
New +$39K 0.02% 224

Other funds holding JNCE

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Grace Capital's JNCE Position: Q4 2021 in Review

Grace Capital held its Jounce Therapeutics, Inc. Common Stock (JNCE) position steady in Q4 2021 at 25,928 shares worth $216K. The position accounts for 0.13% of the portfolio, ranked #135.

Grace Capital first reported a position in JNCE in Q4 2020 and has held it in 5 quarters since. The position peaked at $234K in Q3 2021. 124 funds tracked by Wall St. Rank hold JNCE as of Q4 2021.

  • Grace Capital held 25,928 shares of Jounce Therapeutics, Inc. Common Stock worth $216K as of Q4 2021.
  • Grace Capital left its Jounce Therapeutics, Inc. Common Stock share count unchanged in Q4 2021.
  • Jounce Therapeutics, Inc. Common Stock made up 0.13% of Grace Capital's portfolio in Q4 2021, its #135 holding.
  • Grace Capital first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and has held it in 5 quarters since.
  • Grace Capital's Jounce Therapeutics, Inc. Common Stock position peaked at $234K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.